1.
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
by Cleynen, Isabelle, PhD
The Lancet (British edition), 2016, Vol.387 (10014), p.156-167
2.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase...
by Feagan, Brian G, Prof
The Lancet (British edition), 2017, Vol.389 (10080), p.1699-1709
3.
Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort
by Schnitzler, F
Gut, 2009, Vol.58 (4), p.492-500
4.
Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring
by Benitez, Jose-Manuel
Gut, 2013, Vol.62 (12), p.1806-1816
5.
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
by Arijs, I
Gut, 2009, Vol.58 (12), p.1612-1619
6.
Use of azathioprine in IBD: modern aspects of an old drug
by Louis, Edouard
Gut, 2014, Vol.63 (11), p.1695-1699
7.
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
by Reenaers, C.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (11-12), p.1040-1048
8.
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
by Ferrante, Marc
Gut, 2007, Vol.56 (10), p.1394-1403
9.
FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity
by Saboury, Babak
European journal of nuclear medicine and molecular imaging, 2013, Vol.41 (4), p.605-614
10.
11.
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease
by Louis, E
Gut, 2001, Vol.49 (6), p.777-782
12.
Lactobacillus stress protein GroEL prevents colonic inflammation
by Dias, Alexandre M. M
Journal of gastroenterology, 2021, Vol.56 (5), p.442-455
13.
The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab
by Kopylov, U.
Alimentary pharmacology & therapeutics, 2011, Vol.33 (3), p.349-357
14.
Alveolar echinococcosis in southern Belgium: retrospective experience of a tertiary center
by Cambier, Audrey
European journal of clinical microbiology & infectious diseases, 2018, Vol.37 (6), p.1195-1196
15.
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
by Louis, E.
Alimentary pharmacology & therapeutics, 2004, Vol.19 (5), p.511-519
16.
Occult HCV Infection: The Current State of Knowledge
by Rezaee-Zavareh, Mohammad Saeid
Iranian red crescent medical journal, 2015, Vol.17 (11), p.e34181-e34181
17.
[18F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma
by Withofs, Nadia
European journal of nuclear medicine and molecular imaging, 2015, Vol.43 (4), p.654-662
18.
19.
20.
Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis
by de Seny, Dominique
Annals of the Rheumatic Diseases, 2011, Vol.70 (6), p.1144-1152
